Amgen Inc. (NASDAQ:AMGN) Stock Holdings Increased by Sequoia Financial Advisors LLC

Sequoia Financial Advisors LLC lifted its position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 3.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 149,061 shares of the medical research company's stock after acquiring an additional 5,225 shares during the quarter. Sequoia Financial Advisors LLC's holdings in Amgen were worth $46,440,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of AMGN. Pinney & Scofield Inc. acquired a new stake in Amgen during the 4th quarter valued at $26,000. First Pacific Financial grew its holdings in Amgen by 304.5% during the 1st quarter. First Pacific Financial now owns 89 shares of the medical research company's stock valued at $28,000 after buying an additional 67 shares during the last quarter. Ritter Daniher Financial Advisory LLC DE grew its holdings in Amgen by 66.2% during the 4th quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company's stock valued at $33,000 after buying an additional 51 shares during the last quarter. Synergy Investment Management LLC acquired a new stake in Amgen during the 4th quarter valued at $34,000. Finally, Atala Financial Inc acquired a new stake in Amgen during the 4th quarter valued at $34,000. Hedge funds and other institutional investors own 76.50% of the company's stock.

Amgen Stock Down 0.7%

Shares of Amgen stock traded down $1.98 during trading hours on Friday, hitting $277.13. 2,894,198 shares of the company's stock traded hands, compared to its average volume of 2,833,059. The stock has a 50 day simple moving average of $281.02 and a 200-day simple moving average of $286.01. The company has a quick ratio of 0.88, a current ratio of 1.17 and a debt-to-equity ratio of 8.70. The company has a market cap of $149.02 billion, a PE ratio of 25.29, a PEG ratio of 2.52 and a beta of 0.51. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.85.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share for the quarter, beating the consensus estimate of $4.18 by $0.72. The company had revenue of $8.15 billion during the quarter, compared to the consensus estimate of $8.05 billion. Amgen had a return on equity of 176.11% and a net margin of 17.39%. The company's revenue was up 9.4% on a year-over-year basis. During the same period last year, the firm earned $3.96 earnings per share. Equities research analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. Bank of America increased their target price on Amgen from $275.00 to $294.00 and gave the company an "underperform" rating in a report on Wednesday, March 5th. Royal Bank Of Canada decreased their price objective on Amgen from $324.00 to $320.00 and set an "outperform" rating on the stock in a report on Friday, May 2nd. Wall Street Zen upgraded Amgen from a "buy" rating to a "strong-buy" rating in a report on Sunday, May 18th. Johnson Rice set a $294.00 price objective on Amgen in a report on Wednesday, March 5th. Finally, Cantor Fitzgerald restated a "neutral" rating and set a $305.00 price objective on shares of Amgen in a report on Tuesday. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, Amgen currently has a consensus rating of "Hold" and a consensus target price of $309.22.

Insider Activity

In related news, SVP Rachna Khosla sold 1,500 shares of Amgen stock in a transaction dated Thursday, June 5th. The stock was sold at an average price of $289.68, for a total value of $434,520.00. Following the completion of the transaction, the senior vice president now directly owns 8,162 shares in the company, valued at approximately $2,364,368.16. This trade represents a 15.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.76% of the company's stock.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.